SEC Form 4 · accession 0001214659-26-011731
Aquestive Therapeutics, Inc. · AQST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Barber
Officer — President and CEO · Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 16, 2026 · 2:00 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001398733
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 15, 2026 | S | 25,000 | $4.8195 | D | 652,317 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction involves sale transactions from $4.78 to $4.90 per share. The weighted average price per share was $4.8195. The Reporting Person undertakes to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, information regarding the number of shares sold at each separate price.